Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 3905 results
CHMP grants positive opinions of AbbVie's VIEKIRAX + EXVIERA to treat chronic hepatitis C
The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted positive opinions for AbbVie's investigational, all-oral, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir) + EXVIERA (dasabuvir) with or without ribavirin (RBV) for patients with genotype 1 (GT1) and genotype 4 (GT4) chronic hepatitis C virus (HCV) infection.
Drug Research > Drug Discovery & Development > News
Heptares Orphan disease program awarded grant from UK Biomedical catalyst
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, is pleased to announce that it has been awarded a £1.5 million grant from the UK Biomedical Catalyst, a funding programme jointly operated by the UK Medical Research Council (MRC) and Innovate UK.
Drug Research > Drug Discovery & Development > News
Cynapsus reports positive top-line results from CTH-105 phase II trial of APL-130277 to treat Parkinson's Disease
Cynapsus Therapeutics, a specialty pharmaceutical company focused on Parkinson’s disease, announced positive top-line results from its CTH-105 Phase II clinical trial of APL-130277 for the management of OFF motor symptoms of Parkinson’s disease.
Drug Research > Drug Discovery & Development > News
Teva introduces liquid formulation of Treanda injection in US
By PBR Staff Writer
Teva Pharmaceutical Industries has launched a liquid formulation of Treanda (bendamustine HCI) Injection in the US indicated to treat patients with chronic lymphocytic leukemia (CLL).
Drug Research > Drug Discovery & Development > News
Edge Therapeutics enters research collaboration with leading academic medical center
Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming the treatment of acute, life-threatening neurological conditions, announced a multi-year research and discovery collaboration with St. Michael’s Hospital, which is affiliated with the University of Toronto.
Drug Research > Drug Discovery & Development > News
FDA allows Fibrocell's IND application for new Wounded Warrior Amputees to prevent stump skin diseases
Fibrocell Science, an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced the US Food and Drug Administration is allowing the company's investigational new drug (IND) application to proceed for developing a new treatment for amputee stump skin to prevent skin diseases that lead to prosthesis abandonment.
Drug Research > Drug Discovery & Development > News
Genticel closes patient enrolment in Phase II ProCervix trial
By PBR Staff Writer
French biotechnology firm Genticel has completed patient enrollment in the Phase II trial (RHEIA-VAC) of its lead therapeutic vaccine candidate, ProCervix , to treat human papillomavirus (HPV).
Drug Research > Drug Discovery & Development > News
Alnylam reports positive initial phase II data with Revusiran to treat TTR Cardiac Amyloidosis
Alnylam Pharmaceuticals, a leading RNAi therapeutics company, announced positive initial Phase 2 data with revusiran (ALN-TTRsc), an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR cardiac amyloidosis.
Drug Research > Drug Discovery & Development > News
AstraZeneca begins development programme for BRILINTA reversal agent
AstraZeneca has begun a pre-clinical development programme to evaluate the ability of investigational antibody, MEDI2452, to rapidly and specifically reverse the antiplatelet effects of ticagrelor (BRILINTA) in rare emergency situations such as urgent surgery, or in the event of major bleeding.
Drug Research > Drug Discovery & Development > News
Galmed doses first patient in its Phase IIa trial of aramchol to treat cholesterol gallstones
By PBR Staff Writer
Israel-based Galmed Pharmaceuticals has dosed first patient in its Phase IIa clinical trial of its drug candidate, aramchol, to treat newly formed cholesterol gallstones following bariatric surgery.
Drug Research > Drug Discovery & Development > News
ONL Therapeutics gets Phase II SBIR grant from NEI to develop new retinal disease treatment
By PBR Staff Writer
US-based biopharmaceutical firm ONL Therapeutics has received a $1.37m Small Business Innovation Research (SBIR) Phase II contract from the National Eye Institute (NEI) to advance development of its lead therapeutic candidate ONL101.
Drug Research > Drug Discovery & Development > News
ArQule, NIH collaborate for clinical development of ARQ 092 in proteus syndrome
ArQule has announced an agreement with the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) providing for the clinical development of ARQ 092, an orally available, selective small molecule inhibitor of AKT, in Proteus syndrome, a rare disease characterized by overgrowth of the skeleton, skin, adipose tissue and central nervous system.
Drug Research > Drug Discovery & Development > News
Enanta reports results from TURQUOISE-I study in chronic hepatitis C patients with HIV-1 co-infection
Enanta Pharmaceuticals, a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced at The Liver Meeting 2014 results from studies in chronic hepatitis C virus (HCV) patients with human immunodeficiency virus type 1 (HIV-1) co-infection (TURQUOISE-I) and liver transplant recipients (CORAL-I).
Drug Research > Drug Discovery & Development > News
EnGeneIC, ADRI begin MesomiR-1 Phase I trial in patients with late stage Mesothelioma
EnGeneIC, an emerging biopharmaceutical company focused on developing its proprietary EDV nanocell platform for the targeted delivery of cancer therapeutics and other therapeutic molecules, announced that, together with the Asbestos Disease Research Institute (ADRI), it has initiated the first clinical trial evaluating its bacterially-derived and antibody-guided EDV nanocells packaged with microRNA for the treatment of patients with malignant pleural mesothelioma (MPM).
Drug Research > Drug Discovery & Development > News
BioLineRx reports final results of Phase I/II trial for new celiac treatment
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, has announced successful final results from its Phase I/II study for BL-7010, a novel co-polymer for the treatment of celiac disease.
Drug Research > Drug Discovery & Development > News
91-105 of 3905 results